Published in final edited form as:

Pediatr Infect Dis J. 2018 December ; 37(12): 1271–1278. doi:10.1097/INF.0000000000002082.

Infectious Morbidity, Mortality and Nutrition in HIV-Exposed, Uninfected, Formula Fed Infants: Results from the HPTN 040/PACTG 1043 Trial

Nava Yeganeh, MD, MPH¹, D. Heather Watts, MD², Jiahong Xu, PhD³, Tara Kerin, PhD¹, Esau C. Joao, MD⁴, Jose Henrique Pilotto, MD⁵, Gerhard Theron, MD⁶, Glenda Gray, MD⁷, Breno Santos, MD⁸, Rosana Fonseca, MD⁹, Regis Kreitchmann, MD¹⁰, Jorge Pinto, MD¹¹, Marisa M. Mussi-Pinhata, MD¹², Valdilea Veloso, MD¹³, Margaret Camarca, MPH, RN³, Lynne Mofenson, MD¹⁵, Jack Moyer, MD¹⁴, and Karin Nielsen-Saines, MD, MPH¹

¹David Geffen UCLA School of Medicine, Los Angeles, CA

²Office of the Global AIDS Coordinator and Health Diplomacy, U.S. Dept. of State, Washington D.C

³Westat, Rockville, MD

⁴Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil

⁵Hospital Geral de Nova Iguaçu, Nova Iguaçu and Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, (Fiocruz), Rio de Janeiro, Brazil, Perinatal HIV Research Unit

⁶Stellenbosch University/Tygerberg Hospital, Cape Town, South Africa

⁷University of Witwatersrand/Chris Hani Baragwanath Hospital, Johannesburg, South Africa

⁸Hospital Conceicao, Porto Alegre, RS, Brazil

⁹Hospital Femina, Porto Alegre, RS, Brazil

¹⁰Irmandade da Santa Casa de Misericórdia de Porto Alegre, RS, Brazil

¹¹Federal University of Minas Gerais, Belo Horizonte, MG, Brazil

¹²Universidade de São Paulo, Ribeirão Preto, SP, Brazil

¹³Laboratório de Pesquisa Clínica em DST e AIDS - Instituto de Pesquisa Clínica Evandro Chagas - Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil

¹⁴Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD

Correspondence/Address for Reprints: Nava Yeganeh MD, MPH, Dept of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States. Division of Infectious Disease-MDCC 22-442 10833 Le Conte Ave, Los Angeles, CA 90095. Telephone 310 825-5235. Fax 310-206-4764, nyeganeh@mednet.ucla.edu.

Clinical Trials Registration Number: NCT00099359

Disclaimer:

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institutes of Health, the U.S. Department of Health and Human Services or the U.S. Department of State

¹⁵Elisabeth Glaser Pediatric AIDS Foundation, Washington DC

Abstract

Background—HIV exposed uninfected (HEU) infants are a growing population with potentially poor health outcomes. We evaluated morbidity and mortality in HEU formula-fed infants enrolled in the NICHD HPTN 040/PACTG 1043 trial.

Methods—Infectious morbidity, mortality, and undernutrition were evaluated within a cohort of 1,000 HEU infants enrolled between 4/2004 and 4/2010 in Brazil (N=766) and South Africa (N=234) as part of the NICHD/HPTN 040 trial of three different antiretroviral regimens to decrease intrapartum HIV vertical transmission.

Results—Twenty three percent of infants had at least 1 infectious serious adverse effect (ISAE). Infants born to mothers with <12 years of education (AOR 2.6, 95% CI 1.2–5.9), with maternal viral load of >1,000,000 copies/mL at delivery (AOR 9.9, 95% CI 1.6–63.1) were more likely to have ISAEs. At 6 months, the infant mortality rate per 1,000 live births overall was 22±2.6, 9.1±1.8 in Brazil, and 64.1±3 in South Africa. Undernutrition and stunting peaked at 1 month of age with 18% having a weight for age Z score –2, and 22% with height for Z score –2. The likelihood of infant mortality was greater among infants born in South Africa compared to Brazil (AOR 6.2 95% CI 2.5–15.8), high maternal viral load (AOR 1.7, 95% CI 1.01–2.9) and birth WAZ –2 (AOR 5.2, 95% CI 1.8–14.8).

Conclusions and Relevance—There were high rates of undernutrition, stunting and ISAE in this study's formula fed HEU population. Suppressing maternal HIV viral load during the peripartum period may be a modifiable risk factor to decrease infant mortality.

Keywords

HIV exposed; uninfected infants; formula feeding; undernutrition

Each year, an estimated 1.5 million HIV-infected women give birth in low- and middle income countries (LMIC).¹ Approximately 25–45% of infants born to HIV-infected mothers will become infected without appropriate interventions to prevent mother to child transmission (PMTCT). HIV-infected infants have high morbidity and mortality without prompt initiation of treatment.² However, a number of studies have suggested that HIV-exposed uninfected (HEU) children may also face an increased risk of serious infections and mortality as compared to HIV-unexposed infants, while other data do not support this association.^{3–12} The etiology for possible increased morbidity and mortality in HEU infants is likely multi-factorial, including immunological abnormalities,^{13–16} and lack of parental care,¹⁷ but some authors postulate that lack of breastfeeding by HIV-infected mothers may contribute to this poor outcome.^{18–23} In HEU infants born in Africa, breastfeeding is associated with decreased rates of infectious morbidity, including pneumonia^{3,24,25} and gastroenteritis,²⁶ as well as decreased mortality.²⁷ However, other studies performed in South Africa and Kenya have suggested that there is no difference in morbidity and mortality if there is access to clean water,^{28,29} and recent data suggests a trend towards worse outcomes in HEU infants even when they are breastfed.⁸ Furthermore, it has been well documented that breastfeeding can result in HIV transmission.³⁰ Discouraging

breastfeeding for HIV-infected women presents a dilemma in many developing countries if HEU infants succumb to complications unassociated to HIV but related to formula-feeding.

Given that this is an area of uncertainty and continued investigation, the World Health Organization (WHO) and in-country PMTCT policies are constantly evolving. In LMIC countries, the WHO now recommends that all new mothers on antiretroviral therapy (ART) can breastfeed for 12 months or longer.³¹ South Africa's national policy largely mirrors the WHO recommendations, but the country also provided free formula to HIV infected women until 2011.³² In contrast, Brazilian policies recommend formula feeding regardless of maternal ART, because background infant morbidity and mortality from infections are low and even small increases in the potential for HIV transmission are unacceptable.³³

Given this backdrop, the present study's objective was to evaluate HEU formula-fed infants born to a high-risk population of mothers who were enrolled in a large HIV PMTCT trial for infectious serious adverse events (ISAE), undernutrition, stunting, and mortality during their first 6 months of life.

METHODS

We performed an analysis of data collected as part of the NICHD /HPTN 040 (P1043) study³⁴ which enrolled HIV-infected mothers who had not received antiretroviral drugs prior to labor because of late presentation for medical care or because HIV testing was not performed during pregnancy. Enrollment and infant follow-up for 6 months occurred between April 2004 and January 2011 with primary results published in June 2012. Since the main study endpoint was the comparative efficacy of different infant antiretroviral regimens to prevent *intrapartum* HIV transmission, the study was designed exclusively for formula-fed infants, and formula was provided to all participants. All households had access to clean water. Enrollment occurred at 17 sites in Brazil, South Africa, Argentina and the United States. The study was approved by local and collaborating institutional review boards.

In this analysis, we included all HEU infants who completed 6 months of study follow-up in a selection pool along with live-born HIV-exposed infants who died before the 6 month follow up study visit and who had negative HIV PCR results prior to death. We excluded infants diagnosed with HIV infection, lost to follow-up before age 6 months, or who had any evidence of breastfeeding during the study period. From this selection pool, we included 1,000 infants to perform this analysis initially as part of the Data Safety Monitoring Board recommendations, using a systematic sampling method by study site to guarantee all sites were represented proportionately and infants were selected over the range of time that the study had been in operation. Given that 97.5% of recruitment for the parent study occurred in Brazil and South Africa, we limited this analysis to participants from these two countries.

Study visits occurred at birth, 4 to 7 days, 10 to 14 days, 4 to 6 weeks, 3 months, and 6 months of age. Medical histories were obtained and physical examinations were performed at each visit. Infant gestational age was estimated based on maternal report of last menstrual period. Prenatal ultrasound results, if available, were also used to help verify gestational age.

If neither were available, the site principal investigator estimated the infant's age using the Ballard and Dubowitz scores.

Infants' weight and length were measured at each visit and plotted using the WHO growth charts for each sex. All sites received monitoring visits, periodic trainings, and were supervised on taking infant measurements using an adaptation of the WHO "Measuring a Child's Growth".³⁵ All equipment, including scales, used in the study were checked and rechecked throughout study period with extensive training delivered to site staff for technical procedures such as measuring weight, height and vital signs. Infants with weight-for-age Z-score (WAZ) -2 and >-3 were considered moderately undernourished, and those with WAZ -3 were considered severely undernourished. Infants with height-for-age Z-score (HAZ) -2 and >-3 were considered moderately stunted, and those with HAZ -3 were considered severely stunted. All ISAEs were documented, including congenital infections and infections involving the respiratory system, the gastrointestinal system, and the central nervous system requiring medical care (grade 3), deemed as life-threatening (grade 4) or resulting in death (grade 5). Cause of death was documented on case report forms completed by site principal investigators. Complete blood counts and hepatic aminotransferase levels were measured at all visits except at 6 months. Serious adverse events were graded with the use of the 1993 Division of AIDS Toxicity Tables for Grading Severity of Pediatric Adverse Experiences.³⁶

At study enrollment, mothers were interviewed about risk behaviors, including illegal substance use, alcohol use, tobacco use, as well as receipt of prior prenatal care. Maternal HIV RNA levels, CD4+ T-lymphocyte (CD4) cell subsets, and serologic tests for syphilis were obtained at the time of labor/delivery. Infant data included mode of delivery, birth weight, gestational age, HIV antiretroviral prophylaxis arm, and whether zidovudine was received during the *intrapartum* period by the mother

Statistical Analysis

Two-sample T-test and Chi-square test were used to compare the differences in continuous and categorical variables between two independent samples (as appropriate). Univariate and multivariate logistic regression analyses were performed to assess the relationship of potential predictors with infants having at least one ISAE and with infant mortality. To explore potential risk factors in relation with ISAE and with infant mortality in Brazil and South Africa separately, a stratified logistic regression was performed by infant's birth country. Covariates with a Type III overall p-value <0.15 from univariate models were entered into initial full multivariable model for model selection. Backward, forward, and stepwise model selections were used to select the best final multivariable model. In particular, for the ISAE analysis, birth country, race, years of education, viral load, and WAZ at birth were included in the initial full multivariate model for model selection. For infant mortality analysis, birth country, gestational age at delivery, race, whether the mother received any prenatal care during pregnancy, mode of delivery, viral load, and WAZ at birth were included in the initial full model for model selection. When viral load was less than 400 copies/mL, value was imputed to be 200 copies/mL and considered as undetectable. All computations were done using SAS version 9.3.

RESULTS

Among 1,000 infants, 766 were from Brazil and 234 were from South Africa, maintaining the same proportion of the parent cohort. Table 1 describes baseline characteristics of the women included in this analysis. Fifty percent of infants were female. The majority of mothers were of black or mixed black/white race, were an average of 26 years of age, had relatively high CD4 cell counts (median of 466 cells/mm³), and had detectable viremia at the time of delivery. Ninety percent of women delivered infants at full term (≥ 37 weeks), and mean infant birth weight was 3,017±518g with approximately 7% of full term infants being born small for gestational age. Mean infant birth weights were significantly lower in South Africa as compared to Brazil. As with the primary analysis, many women had received prenatal care but had not been identified and/or treated as HIV-infected.

Approximately 23% of all infants (n= 229) experienced one or more ISAE during the 6 month follow up; 19% in South Africa (n= 44) and 24% in Brazil (n= 185). Figure 1 shows the frequency of ISAEs in the cohort. Adjusted per infant years (IY), the overall rate of ISAEs was 60/100 IY; with similar rates between Brazil and South Africa (61 vs. 59/100 IY), but varying by type of ISAE. Gastrointestinal ISAEs were more common in South Africa with rates (95% CI) of 24.2/100 IY (15.1–33.3/100 IY) vs. 4.7/100 IY in Brazil (2.5–6.9/100 IY), whereas congenital ISAEs were more frequently diagnosed in Brazil, 21.8/100 IY (17.1–26.5/100 IY) vs. 3.6/100 IY (0.97–9.14/100 IY) in South Africa, primarily due to high congenital syphilis rates in Brazil.

Participating infants' vaccination status (see table, Supplemental Digital Content 1) shows that only 1.3% of infants in South Africa and 41% of infants in Brazil received immunization against rotavirus. Of note, rotavirus vaccine was unavailable during the majority of the study duration as it became available in Brazil in 2006 and in S. Africa in 2009.³⁷ Furthermore, only 1.6% of infants in Brazil and none in South Africa received pneumococcal conjugate vaccine, which was made available in both countries in 2009.³⁷

As seen on Table 2, the multivariate logistic regression model demonstrated that the probability of having at least one ISAE (Grade 3–5) in formula-fed infants was associated with less than 12 years of maternal education compared with women with ≥ 12 years of education (adjusted odds ratio [AOR] (95% CI)): <8 years, 3.7 (1.7–7.8), 8 years, 3.5 (1.5–8.1), and 9–11 years, 2.6 (1.2–5.9). Similarly, having one ISAE was associated with maternal viral load at delivery of greater than 1,000,000 copies/mL as compared with undetectable viral load (AOR 9.9, 95% CI 1.6–63.1). There were 101 instances of neutropenia recorded but only 6 patients with neutropenia probably or possibly secondary to zidovudine had an ISAE.

Undernutrition and stunting peaked at age 1 month in both countries (Figure 2). Both WAZ and HAZ improved by age 6 months in Brazil (p<0.001), but only WAZ improved statistically in South Africa by age 6 months (p<0.001 for WAZ, p =0.6 for HAZ). At age 1 month, 18% of all infants were undernourished (16% in Brazil and 23% in South Africa) and 22% were stunted (21% in Brazil and 25% in South Africa). At age 3 months, 12% of all infants were undernourished (11% in Brazil and 16% in South Africa) and 18% were

stunted (17% in Brazil and 24% in South Africa). At age 6 months, 7.3% of all participants were undernourished (6.3% in Brazil and 11% in South Africa) and 14% were stunted (11% in Brazil and 26% in South Africa).

In Brazil, 7 (0.9%) infants died and 15 infants (6.4%) died in South Africa (Table 3). Among deaths in Brazil, 4 infants died from pneumonia and 3 succumbed to sepsis. The mean age of death was 114 days (range, 12–150 days) with an infant mortality rate (IMR, mean $\pm$ SD) per 1,000 of 9.1 ± 1.8 at 6 months of age. In South Africa, 4 infants died from pneumonia, 3 from gastroenteritis, 2 from sepsis, 5 from Sudden Infant Death Syndrome (as determined by site investigators), and 1 with congenital syphilis. The mean age of death in South Africa was 34.7 days (range, 1–196) with an IMR of 64.1 ± 3.0 at 6 months of age. In the final model, infant mortality was associated with South African birth (AOR 6.2, 95% CI 2.5–15.8); maternal viral load at delivery, (AOR per 1 Log₁₀ increment: 1.7, 95% CI 1.01–2.9); and low birth WAZ (birth WAZ -2 to >-3 AOR 5.2, 95% CI 1.8–14.8; birth WAZ -3 AOR 6.2, 95% CI 1.8–21.3), compared with WAZ >-2 . In the univariate analysis, gestational age <37 weeks, black race, and lack of prenatal care were significantly associated with infant mortality, but not in the final multivariable model. In the unadjusted model, cesarean section delivery was protective. As 93% of the cesarean sections were performed in Brazil, and the lower infant mortality in Brazil likely confounded the univariate results.

DISCUSSION

In this population of formula-fed HEU infants born to mothers who did not receive ART before labor and delivery, there were high rates of syphilis, cytomegalovirus, gonorrhea and chlamydia co-infections in both mothers and infants in this cohort.^{38–40} In addition, given the growing evidence that HEU infants may be more vulnerable to infections and mortality compared to the general population, especially in the absence of breastfeeding, high rates of adverse events in the cohort were anticipated.

The high rates of undernutrition and stunting in our formula-fed cohort are consistent with results prior studies.⁴¹ In Brazil, WHO reported that 5.1% of all infants in the general population between 0 and 6 months of age suffered undernutrition between 2006–2007, a lower proportion than the 6.3% observed in our vulnerable HEU cohort.⁴² However, in South Africa, WHO reported that 15.8% of infants 0 and 6 months were undernourished between 2003–2005,^{43,44} which is significantly higher than the 11% observed in this cohort. Of note, we used the WHO growth charts for our measurements as they are accepted as the standard guide in both Brazil and South Africa, which were developed by measuring breastfeeding infants. Given that formula fed infants tend to gain weight faster during infancy as compared to breastfeeding infants,⁴⁵ there may be some underestimation of the level of undernutrition in our formula fed population.

We noted that rates of stunting and undernutrition peaked at 1 month of life and improved by 6 months of life. It is unknown if in utero exposure to HIV or exposure to antiretrovirals during the first few weeks of life contributed to these high rates of undernutrition and stunting. Nevirapine based regimens have been associated with improved growth in infants with HIV infection.⁴⁶ Our analyses did not support differing rates of undernutrition with any

of the infant prophylaxis regimens, but we were using short courses of nevirapine and nelfinavir as prophylaxis regimens in HEU infants, and not as treatment. Furthermore, infants in our study did not have antenatal exposure to antiretroviral drugs. With 53–55% of all childhood deaths attributable to undernutrition,^{47–49} optimizing the nutritional status of HEU infants should be an area of intense evaluation.

Although rare, viral loads greater than 1 million copies/mL were associated with increased rates of infectious serious adverse events, supporting an association between maternal viral load and infections in HEU infants as reported by other investigators from South Africa, Zambia and Kenya.^{18,28,50–52} Maternal viral load could potentiate dysregulation of an infant's immune system, as higher maternal viral loads have been associated with decreased maternal antibody transfer during the third trimester, decreased number of circulating T cells and impaired T cell maturation in HEU infants.^{53,54} In addition, the immunologic properties of breast milk may vary considerably between women with immune reconstitution following antiretroviral treatment versus those with advanced HIV disease.^{55,56} Furthermore, HIV-infected mothers with high-level viremia may be more physically affected by disease and less able to provide appropriate childcare to their infants compared to healthy mothers. As maternal viral load is a known major predictor of perinatal HIV transmission,⁵⁷ every effort must be taken to suppress viremia as quickly and as early as possible in HIV-infected women in order to promote maternal health, to reduce transmission, and to potentially reduce morbidity and mortality in HEU infants. Evidence has been inconclusive as to whether the higher susceptibility to infections in HEU infants is due to potential HIV exposure in utero or antiretroviral drug exposure during pregnancy and breastfeeding.^{58,59} Our study supports the hypothesis that increased morbidity and mortality in HEU infants may be potentially due to exposure to maternal HIV, since infants in this study were not exposed to antiretroviral drugs *in utero* or through breastmilk.

In general, rates of ISAEs in our cohort were similar or lower than those reported in other studies looking at hospitalizations, infectious pneumonia and gastroenteritis in formula fed HEU infants in Brazil and South Africa.^{28,50} When comparing rates of ISAE (focused on gastroenteritis and lower respiratory tract infection) as described by the Kesho Bora study which included sites in South Africa, our rate of 44.8/100IY was similar to their rate of 47.2/100IY in the “never breastfeeding group,” but notably higher than the rates of 10.9/100IY reported in the exclusively breastfed population.¹⁰ Similarly, our calculated IMR of 64.1/1,000 live births in the South African infants is similar to IMR reported by other studies performed in South Africa with formula-fed infants, but higher than the IMR reported in South African breastfed infants of 35–51/1,000 live births^{28,51} and higher than IMR for South Africa as reported by UNICEF (52.8/1000 live births in 2004 decreased to 37.1/1000 live births in 2011).⁶⁰ Our calculated IMR of 9.1/1,000 in Brazil was lower than general population IMRs reported for Brazil (21/1000 live births in 2004 decreased to 14.4/1000 live births in 2011).⁶⁰

Both Brazil and South Africa are upper middle-income countries with growing populations of HEU infants. While our study provides evidence for possible contributors to morbidity and mortality in this population, it has weaknesses. First, this was a clinical research study with close medical follow-up of patients, which may limit the generalizability of results.

Second, we did not have a control arm of HEU breastfed infants since the parent study excluded breastfeeding infants. However, we were able to compare our data with other studies done in similar populations. At the time of this study, formula feeding was an acceptable option for HIV infected women in South Africa, and thus, our study is unique in being able to collect and analyze extensive information on infant outcomes for a very large cohort of formula fed HEU infants with very close follow up. Our findings support the WHO recommendations as well as the South African 2015 National Consolidated Guidelines for PMTCT, promoting breastfeeding as an important option for HIV-infected African women who are on appropriate ART as breastfeeding appears to decrease incidence of infectious morbidity and mortality.^{32,61,62}

Conclusion

In conclusion, birth WAZ scores and high maternal HIV viral load were significantly associated with infant morbidity and mortality in formula fed HEU infants. Given high rates of diarrhea and pneumonia reported in this population, prompt and complete vaccination against rotavirus and pneumococcal infections in these high-risk infants is of paramount importance. Addressing these modifiable risk factors could improve morbidity and mortality in infants born to HIV-infected women.

Acknowledgments

Funding Source: The NICHD HPTN 040 study was supported by NICHD Contract # HHSN267200800001C (NICHD Control # N01-HD-8-0001) and U01 AI047986 (Brazilian AIDS Prevention Trials International Network), NIAID/ NIH. Dr. Yeganeh received funding from the NIAID (K23 AI118584). Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) [U01 AI068632], the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD), and the National Institute of Mental Health (NIMH) [AI068632]. In addition, the study was supported in part by Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), and GlaxoSmithKline on behalf of ViiV Healthcare. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) and were fully responsible for all aspects of manuscript development. Boehringer-Ingelheim Pharmaceuticals, Inc and GlaxoSmithKline were given the opportunity to check the data used in the present manuscript for factual accuracy only. We thank the patients and their families who enrolled in this trial; and Marita McDonough and Lauren Petrella from Boehringer Ingelheim Pharmaceuticals and Helen Watson from GlaxoSmithKline (on behalf of ViiV Healthcare) for assistance with the donation of study drugs from their respective companies for the conduct of the study. Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH nor the US Department of State.

References

1. World Health Organization. HIV/AIDS fact sheet no 360. 2014. <http://www.who.int/mediacentre/factsheets/fs360/en/>
2. Wiktor SZ, Ekpin E, Nduati RW. Prevention of mother-to-child transmission of HIV-1 in Africa. *AIDS*. 1997; 11(Suppl B):S79–87.
3. Koyanagi A, Humphrey JH, Ntozini R, et al. Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy. *The Pediatric Infectious Disease Journal*. 2011; 30(1):45–51. [PubMed: 21173675]

4. Kurewa EN, Gumbo FZ, Munjoma MW, et al. Effect of maternal HIV status on infant mortality: evidence from a 9-month follow-up of mothers and their infants in Zimbabwe. *Journal of Perinatology*. 2010; 30(2):88–92.
5. Zaba B, Whitworth J, Marston M, et al. HIV and mortality of mothers and children: evidence from cohort studies in Uganda, Tanzania, and Malawi. *Epidemiology*. 2005; 16(3):275–280. [PubMed: 15824540]
6. Slogrove A, Reikie B, Naidoo S, et al. HIV-exposed uninfected infants are at increased risk for severe infections in the first year of life. *Journal of Tropical Pediatrics*. 2012; 58(6):505–508. [PubMed: 22555385]
7. Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination. *The Lancet Infectious Diseases*. 2016; 16(6):e92–e107. [PubMed: 27049574]
8. Slogrove AL, Esser MM, Cotton MF, et al. A Prospective Cohort Study of Common Childhood Infections in South African HIV-exposed Uninfected and HIV-unexposed Infants. *The Pediatric infectious Disease Journal*. 2017; 36(2):e38–e44. [PubMed: 28081048]
9. Marinda E, Humphrey JH, Iliff PJ, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. *The Pediatric infectious Disease Journal*. 2007; 26(6):519–526. [PubMed: 17529870]
10. Bork KA, Cournil A, Read JS, et al. Morbidity in relation to feeding mode in African HIV-exposed, uninfected infants during the first 6 mo of life: the Kesho Bora study. *The American Journal of Clinical Nutrition*. 2014; 100(6):1559–1568. [PubMed: 25411291]
11. Fawzy A, Arpadi S, Kankasa C, et al. Early weaning increases diarrhea morbidity and mortality among uninfected children born to HIV-infected mothers in Zambia. *J Infect Dis*. 2011; 203(9): 1222–1230. [PubMed: 21459815]
12. Epalza C, Goetghebuer T, Hainaut M, et al. High incidence of invasive group B streptococcal infections in HIV-exposed uninfected infants. *Pediatrics*. 2010; 126(3):e631–638. [PubMed: 20732944]
13. Kidzeru EB, Hesselning AC, Passmore JA, et al. In-utero exposure to maternal HIV infection alters T-cell immune responses to vaccination in HIV-uninfected infants. *AIDS*. 2014; 28(10):1421–1430. [PubMed: 24785950]
14. Slogrove AL, Cotton MF, Esser MM. Severe infections in HIV-exposed uninfected infants: clinical evidence of immunodeficiency. *Journal of Tropical Pediatrics*. 2010; 56(2):75–81. [PubMed: 19602487]
15. Smith C, Jalbert E, de Almeida V, et al. Altered Natural Killer Cell Function in HIV-Exposed Uninfected Infants. *Front Immunol*. 2017; 8:470. [PubMed: 28484464]
16. Garcia-Knight MA, Nduati E, Hassan AS, et al. Altered Memory T-Cell Responses to Bacillus Calmette-Guerin and Tetanus Toxoid Vaccination and Altered Cytokine Responses to Polyclonal Stimulation in HIV-Exposed Uninfected Kenyan Infants. *PLoS One*. 2015; 10(11):e0143043. [PubMed: 26569505]
17. Watts H, Gregson S, Saito S, Lopman B, Beasley M, Monasch R. Poorer health and nutritional outcomes in orphans and vulnerable young children not explained by greater exposure to extreme poverty in Zimbabwe. *Trop Med Int Health*. 2007; 12(5):584–593. [PubMed: 17445126]
18. Asbjornsdottir KH, Slyker JA, Maleche-Obimbo E, et al. Breastfeeding Is Associated with Decreased Risk of Hospitalization among HIV-Exposed, Uninfected Kenyan Infants. *Journal of Human Lactation : Official journal of International Lactation Consultant Association*. 2015
19. Doherty T, Sanders D, Goga A, Jackson D. Implications of the new WHO guidelines on HIV and infant feeding for child survival in South Africa. *Bulletin of the World Health Organization*. 2011; 89(1):62–67. [PubMed: 21346892]
20. Shapiro RL, Lockman S, Kim S, et al. Infant morbidity, mortality, and breast milk immunologic profiles among breast-feeding HIV-infected and HIV-uninfected women in Botswana. *J Infect Dis*. 2007; 196(4):562–569. [PubMed: 17624842]
21. Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? *Lancet*. 2003; 361(9376):2226–2234. [PubMed: 12842379]

22. Kuhn L, Kasonde P, Sinkala M, et al. Prolonged breast-feeding and mortality up to two years post-partum among HIV-positive women in Zambia. *AIDS*. 2005; 19(15):1677–1681. [PubMed: 16184038]
23. Coutoudis A. Breastfeeding and the HIV positive mother: the debate continues. *Early Human Development*. 2005; 81(1):87–93. [PubMed: 15707719]
24. von Mollendorf C, Cohen C, de Gouveia L, et al. Risk factors for invasive pneumococcal disease among children less than 5 years of age in a high HIV prevalence setting, South Africa, 2010 to 2012. *The Pediatric Infectious Disease Journal*. 2015; 34(1):27–34. [PubMed: 24992122]
25. Kelly MS, Wirth KE, Steenhoff AP, et al. Treatment Failures and Excess Mortality Among HIV-Exposed, Uninfected Children With Pneumonia. *J Pediatric Infect Dis Soc*. 2015; 4(4):e117–126. [PubMed: 26582879]
26. Kafalufu G, Hoover DR, Taha TE, et al. Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. *Journal of Acquired Immune Deficiency Syndromes*. 2010; 53(1):6–13. [PubMed: 19844183]
27. Fox MP, Brooks D, Kuhn L, et al. Reduced mortality associated with breast-feeding-acquired HIV infection and breast-feeding among HIV-infected children in Zambia. *Journal of Acquired Immune Deficiency Syndromes*. 2008; 48(1):90–96. [PubMed: 18344878]
28. Venkatesh KK, de Bruyn G, Marinda E, et al. Morbidity and mortality among infants born to HIV-infected women in South Africa: implications for child health in resource-limited settings. *Journal of Tropical Pediatrics*. 2011; 57(2):109–119. [PubMed: 20601692]
29. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. *JAMA*. 2000; 283(9):1167–1174. [PubMed: 10703779]
30. Coutoudis A, et al. Breastfeeding Group HIVITS. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. *J Infect Dis*. 2004; 189(12):2154–2166. [PubMed: 15181561]
31. World Health Organization. [Accessed June 28, 2016] Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection - Recommendations for a public health approach. 2016. <http://www.who.int/hiv/pub/arv/arv-2016/en/>
32. Department of Health for the Republic of South Africa. National Consolidated Guidelines for PMTCT and the Management of HIV in Infants, Children and Adults. Pretoria, South Africa: Department of Health; 2015.
33. Coordenação Nacional de DST/Aids. [Accessed April 1, 2016] Recomendações para profilaxia da transmissão vertical do HIV e terapia antirretroviral em gestantes [National STD / AIDS. Recommendations for prevention of vertical transmission of HIV and antiretroviral therapy in pregnant women]. 2010. http://bvsms.saude.gov.br/bvs/publicacoes/recomendacoes_profilaxia_transmissao_vertical_hiv_5ed.pdf
34. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. *The New England Journal of Medicine*. 2012; 366(25):2368–2379. [PubMed: 22716975]
35. World Health Organization. [Accessed October 12, 2017] WHO Child Growth Standards. 2006. www.who.int/childgrowth/standards/Technical_report.pdf
36. Division of AIDS (DAIDS) Regulatory Support Center. [Accessed December 15, 2016] Table for grading severity of pediatric adverse experiences: less than 3 months. 1994. <http://rsc.tech-res.com/safetyandpharmacovigilance/gradingtables.aspx>
37. Organization WH. [Accessed December 12, 2016] Immunization surveillance, assessment and monitoring. 2012. http://www.who.int/immunization/monitoring_surveillance/en/
38. Adachi K, Klausner JD, Bristow CC, et al. Chlamydia and Gonorrhea in HIV-Infected Pregnant Women and Infant HIV Transmission. *Sexually Transmitted Diseases*. 2015; 42(10):554–565. [PubMed: 26372927]
39. Yeganeh N, Watts HD, Camarca M, et al. Syphilis in HIV-infected mothers and infants: results from the NICHD/HPTN 040 study. *The Pediatric Infectious Disease Journal*. 2015; 34(3):e52–57. [PubMed: 25742089]

40. Adachi K, Xu J, Ank B, et al. Cytomegalovirus Urinary Shedding in HIV-infected Pregnant Women and Congenital Cytomegalovirus Infection. *Clin Infect Dis*. 2017; 65(3):405–413. [PubMed: 28369278]
41. Omoni AO, Ntozini R, Evans C, et al. Child Growth According to Maternal and Child HIV Status in Zimbabwe. *The Pediatric Infectious Disease Journal*. 2017
42. World Health Organization. [Accessed April 1, 2016] Brazil: Child malnutrition estimates by WHO Child Growth Standards. 2012. <http://www.who.int/nutgrowthdb/database/countries/bra/en/>
43. UNICEF, WHO, The World Bank. [Accessed April 1 2016] Global Database on Child Growth and Malnutrition. 2015. <http://apps.who.int/nutrition/landscape/report.aspx?iso=bra>
44. World Health Organization. [Accessed April 1, 2016] South Africa: WHO Global Database on Child Growth and Malnutrition. 2012. http://www.who.int/nutgrowthdb/database/countries/who_standards/zaf.pdf?ua=1
45. Dewey KG. Growth patterns of breastfed infants and the current status of growth charts for infants. *Journal of Human Lactation : Official Journal of International Lactation Consultant Association*. 1998; 14(2):89–92. [PubMed: 9775837]
46. Barlow-Mosha L, Angelidou K, Lindsey J, et al. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. *Clin Infect Dis*. 2016; 63(8):1113–1121. [PubMed: 27439527]
47. Pelletier DL, Frongillo EA Jr, Habicht JP. Epidemiologic evidence for a potentiating effect of malnutrition on child mortality. *American Journal of Public Health*. 1993; 83(8):1130–1133. [PubMed: 8342721]
48. Caulfield LE, de Onis M, Blossner M, Black RE. Undernutrition as an underlying cause of child deaths associated with diarrhea, pneumonia, malaria, and measles. *The American Journal of Clinical Nutrition*. 2004; 80(1):193–198. [PubMed: 15213048]
49. Pelletier DL, Frongillo EA Jr, Schroeder DG, Habicht JP. The effects of malnutrition on child mortality in developing countries. *Bulletin of the World Health Organization*. 1995; 73(4):443–448. [PubMed: 7554015]
50. Mussi-Pinhata MM, Freimanis L, Yamamoto AY, et al. Infectious disease morbidity among young HIV-1-exposed but uninfected infants in Latin American and Caribbean countries: the National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study. *Pediatrics*. 2007; 119(3):e694–704. [PubMed: 17296782]
51. Chopra M, Doherty T, Goga A, Jackson D, Persson LA. Survival of infants in the context of prevention of mother to child HIV transmission in South Africa. *Acta Paediatrica*. 2010; 99(5): 694–698. [PubMed: 20096027]
52. Kuhn L, Kasonde P, Sinkala M, et al. Does severity of HIV disease in HIV-infected mothers affect mortality and morbidity among their uninfected infants? *Clin Infect Dis*. 2005; 41(11):1654–1661. [PubMed: 16267740]
53. Abu-Raya B, Kollmann TR, Marchant A, MacGillivray DM. The Immune System of HIV-Exposed Uninfected Infants. *Front Immunol*. 2016; 7:383. [PubMed: 27733852]
54. Farquhar C, Nduati R, Haigwood N, et al. High maternal HIV-1 viral load during pregnancy is associated with reduced placental transfer of measles IgG antibody. *Journal of Acquired Immune Deficiency Syndromes*. 2005; 40(4):494–497. [PubMed: 16280707]
55. Wahl A, Baker C, Spagnuolo RA, et al. Breast Milk of HIV-Positive Mothers Has Potent and Species-Specific In Vivo HIV-Inhibitory Activity. *Journal of Virology*. 2015; 89(21):10868–10878. [PubMed: 26292320]
56. Kuhn L, Kim HY, Hsiao L, et al. Oligosaccharide composition of breast milk influences survival of uninfected children born to HIV-infected mothers in Lusaka, Zambia. *The Journal of Nutrition*. 2015; 145(1):66–72. [PubMed: 25527660]
57. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. *Pediatric AIDS Clinical Trials Group Study 185 Team*. *The New England Journal of Medicine*. 1999; 341(6):385–393. [PubMed: 10432323]

58. Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-Jones SL. HIV-exposed uninfected children: a growing population with a vulnerable immune system? *Clinical and Experimental Immunology*. 2014; 176(1):11–22. [PubMed: 24325737]
59. Noguera-Julian A, Moren C, Rovira N, et al. Decreased Mitochondrial Function Among Healthy Infants Exposed to Antiretrovirals During Gestation, Delivery and the Neonatal Period. *The Pediatric Infectious Disease Journal*. 2015; 34(12):1349–1354. [PubMed: 26372453]
60. UNICEF. [Accessed October 12, 2017] Child Survival: Under 5 mortality. Child Mortality Estimates. 2015. <http://data.unicef.org/child-mortality/under-five.html>
61. Newburg DS. Neonatal protection by an innate immune system of human milk consisting of oligosaccharides and glycans. *Journal of animal science*. 2009; 87(13 Suppl):26–34. [PubMed: 19028867]
62. Hanson LA. Session 1: Feeding and infant development breast-feeding and immune function. *The Proceedings of the Nutrition Society*. 2007; 66(3):384–396. [PubMed: 17637091]

Figure 1.

Infectious Serious Adverse Events (ISAEs) among Infants from Brazil and South Africa. Y-axis indicates rates of disease per 100 infant years and X-axis indicates infectious categories evaluated. Overall rates of ISAEs per 100 infant years are in dark gray bars, Brazilian ISAE rates per 100 infant years are in midgray bars and South African ISAE rates per 100 infant years are in light gray bars as shown in legend. Gastrointestinal ISAEs were more common in South Africa whereas congenital ISAEs were more frequently diagnosed in Brazil.

Figure 2. Height for Age Z score (HAZ) and Weight for Age Z scores (WAZ) by Study Visit among 1000 infants from Brazil and South Africa. As seen, undernutrition and stunting peaked at 1 month and undernutrition improved by 6 months in both countries.

Table 1
Demographics, Clinical and Obstetric Parameters for Brazilian and South African Infants

	Total	South Africa	Brazil	p-value
Maternal race, n (%)				
White	208 (21.1)	0 (0.0)	208 (27.4)	<.0001
Black	480 (48.6)	222 (96.5)	258 (30.0)	
Brazilian native	9 (0.9)	0 (0.0)	9 (1.2)	
Mixed/Mulatto	283 (28.6)	0 (0.0)	283 (37.3)	
Other	8 (0.8)	8 (3.5)	0 (0.0)	
Maternal age (years)				
n	988	230	758	0.0005
Mean (std. dev.)	27.0 (6.2)	28.2 (6.0)	26.6 (6.2)	
Maternal CD4 count at entry (cells/mm ³)				
n	970	228	742	0.7031
Median (min.– max.)	466 (12–2556)	461 (41–2556)	468 (12–2160)	
Maternal viral load at entry (copies/mm ³)				
n	986	230	756	0.5960
Median (min.– max.)	13580 (200–1526786)	13030 (200–1210000)	14084.5 (200–1526786)	
Mother received prenatal care?				
Yes	660 (67.1)	84 (36.5)	576 (76.4)	<.0001
No	324 (32.9)	146 (63.5)	178 (23.6)	
Number of prenatal care visits				
0	324 (33.2)	146 (64.3)	178 (23.7)	<.0001
1–2	161 (16.5)	36 (15.9)	125 (16.7)	
3+	492 (50.4)	45 (19.8)	447 (59.6)	
Birth weight (g)				
n	1000	234	766	<.0001
Mean (std. dev.)	3017.3 (517.9)	2855.7 (506.3)	3065.9 (512.8)	
Gestational age, n (%)				
32–36 weeks	105 (10.5)	36 (15.4)	69 (9.0)	0.0054
37 weeks	895 (89.5)	198 (84.6)	697 (91.0)	

Table 2
Relationship of Infectious Serious Adverse Events (ISAE) with Infant & Maternal Characteristics

	(Infants with 1 ISAEs)/N (%) [†]	Brazil		South Africa		Both sites		p-value
		OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)			
<u>Infant's characteristics</u>								
Birth country								
Brazil	185/766 (24.2)					1		
South Africa	44/234 (18.8)					0.7 (0.5 – 1.1)		
Gestational age at delivery (wks)								
37	201/895 (22.5)	1	1	1	1			
32–36	28/105 (26.7)	1.2 (0.7–2.1)	1.6 (0.7–1.5)			1.3 (0.8 – 2)		
<u>Maternal baseline characteristics</u>								
Race								
White and others	41/216 (19)	1	1	1	1			
Black	100/480 (20.8)	1.4 (0.9–2.1)	0.4 (0.1–1.6)			1.1 (0.8 – 1.7)		
Brazilian native &Mixed	85/292 (29.1)	1.8 (1.2–2.8)	--			1.8 (1.2 – 2.7)		
Years of education								
12+ years	8/91 (8.8)	1	1	1	1		1	
9–11 years	48/238 (20.2)	2.5 (0.7–8.8)	2.6 (0.9–7.2)			2.6 (1.2 – 5.8)		0.02
Completed 8 years	29/117 (24.8)	2.7 (0.7–9.7)	5.6 (1.5–20)			3.4 (1.5 – 7.9)		0.004
<8 years	140/541 (25.9)	3.1 (0.9–10.4)	4.8 (1.4–16)			3.6 (1.7 – 7.7)		0.001
<u>Maternal characteristics</u>								
Prenatal care?								
Yes	147/660 (22.3)	1	1	1	1			
No	76/324 (23.5)	1.3 (0.9–2)	0.9 (0.4–1.7)			1.1 (0.8 – 1.5)		
Log10 viral load, continuous	225/986 (22.8)	1.1 (0.9–1.3)	1.1 (0.8–1.5)			1.1 (0.9 – 1.3)		
Viral load, copies/mL								
Undetectable	13/73 (17.8)	1	1	1	1		1	
<10,000	90/362 (24.9)	1.3 (0.6–2.6)	2.7 (0.6–12.6)			1.5 (0.8 – 2.9)		0.31
<10,001–100000	91/437 (20.8)	0.95 (0.5–1.9)	2.6 (0.6–12)			1.2 (0.6 – 2.3)		0.71
100,001–1,000,000	27/108 (25)	1.5 (0.7–3.5)	1.8 (0.3–10)			1.5 (0.7 – 3.2)		0.34

		1 ISAEs/N (%) [†]	Both sites			p-value
			Brazil	South Africa	Adjusted OR (95% CI)	
	(Infants with		OR (95% CI)	OR (95% CI)	OR (95% CI)	
>1,000,000	4/6 (66.7)		7.1 (0.6–86)	21 (1.3–346)	9.2 (1.5–56)	0.02
CD4 count (cells/mm3)						
>500	91/438 (20.8)		1	1	1	
200–500	101/428 (23.6)		1.2 (0.8–1.7)	1.3 (0.6–2.7)	1.2 (0.9–1.6)	
<200	27/104 (26)		1.2 (0.7–2.1)	2.2 (0.8–6)	1.3 (0.8–2.2)	
<u>Additional Covariates</u>						
WAZ [*] at birth						
> –2 SD	193/886 (21.8)		1	1	1	
>3, –2 SD	20/72 (27.8)		1.2 (0.6–2.4)	2 (0.8–5.2)	1.4 (0.8–2.4)	
–3 SD	16/42 (38.1)		2.9 (1.4–5.2)	1.6 (0.5–5.4)	2.2 (1.2–4.2)	
WAZ [*] at 1 month						
> –2 SD	167/810 (20.6)		1	1	1	
–2 SD, >–3	31/111 (27.9)		1.3 (0.8–2.2)	2.6 (1.1–6.4)	1.5 (1–2.3)	
–3 SD	25/62 (40.3)		2.7 (1.4–5.2)	3.1 (1.1–8.4)	2.6 (1.5–4.4)	
Illegal substances this pregnancy?						
No	202/901 (22.4)		1	1	1	
Yes	22/83 (26.5)		1 (0.6–1.8)	--	1.3 (0.8–2.1)	
Alcohol use this pregnancy?						
No(never)	140/630 (22.2)		1	1	1	
Yes	83/351 (23.7)		1 (0.8–1.7)	1.1 (0.5–2.5)	1.1 (0.8–1.5)	

[†]The numerator is the total number of infants who had at least 1 infectious serious adverse event (ISAE)

^{*}WAZ: Weight for Age Z score

Table 3
Relationship of Infant Mortality with Maternal Characteristics and Undernutrition status

	Brazil		South Africa		Both sites		p-value
	Death/N (%)	OR (95% CI)	OR (95% CI)	OR (95% CI)	Adjusted OR (95% CI)		
<i><u>Infant's characteristics</u></i>							
Birth country							
Brazil	7/766 (0.91)			1	1		
South Africa	15/234 (6.4)				7.4 (3 – 19)	6.22 (2.5– 16)	<0.001
Gestational age at delivery							
37 weeks	15/895 (1.7)	1	1	1			
32–36 weeks	7/105 (6.7)	1.69 (0.2–14.3)	4.2 (1.4–4.6)	4.2 (1.7 – 10.5)			
<i><u>Maternal baseline characteristics</u></i>							
Age (years)							
24	10/380 (2.6)	1.5 (0.25–INF)	1.5 (0.5–4.6)	1.2 (0.5 – 3)			
25–34	10/467 (2.1)	1	1	1			
35	2/141 (1.4)	--	0.8 (0.2–4)	0.7 (0.1 – 3)			
Race							
White and others	0/216 (0)	1	1	--			
Black	16/480 (3.3)	0.81 (0.02–INF)	0.8 (0.11–INF)	1.6 (0.6–4.3)			
Brazilian native &Mixed/Mulatto	6/292 (2.1)	5.9 (0.9–INF)	--	1			
Years of education							
12+ years	2/91 (2.2)	1	1	1			
9–11 years	8/238 (3.4)	--	2.2 (0.4–10.4)	1.6 (0.3 – 7.4)			
Completed 8 years	3/117 (2.6)	0.3 (0.01–INF)	3.1 (0.4–23.6)	1.2 (0.2 – 7.2)			
<8 years	9/541 (1.7)	0.5 (0.07–INF)	3.3 (0.5–20.8)	0.8 (0.2 – 3.5)			
<i><u>Maternal characteristics at delivery</u></i>							
Prenatal care during pregnancy?							
Yes	8/660 (1.2)	1	1	1			
No	14/324 (4.3)	1.3 (0.3–6.8)	2.4 (0.7–8.8)	3.7 (1.5 – 8.9)			
Mode of delivery							
Vaginal	20/605 (3.3)	1	1	1			

	Brazil		South Africa		Both sites		
	Death/N (%)	OR (95% CI)	OR (95% CI)	OR (95% CI)	Adjusted OR (95% CI)	p-value	
Cesarean sections	2/382 (0.5)	0.2 (0.02–1.6)	0.5 (0.06–3.9)	0.2 (0.04 – 0.7)			
Viral load, Log ₁₀ copies/mL	22/986 (2.2)	2.9 (1.03–8.3)	1.5 (0.8–2.6)	1.9 (1.1 – 3.3)	1.7 (1.01– 2.9)	0.048	
Viral load, copies/mL							
Undetectable	1/73 (1.4)	1	1	1			
<10,000	4/362 (1.1)	--	1.2 (0.1 – 11)	0.8 (0.1 – 7.3)			
10,001–100,000	13/437 (3)	1.19 (0.17–INF)	1.8 (0.2 – 15)	2.2 (0.3 – 17)			
100,001–1,000,000	3/108 (2.8)	0.68 (0.02–INF)	1.4(0.1 – 16)	2.1 (0.2 – 20)			
>1,000,000	1/6 (16.7)	--	11 (0.5 – 250)	14.4 (0.8 – 266)			
CD4 count (cells/mm3)							
>500	7/438 (1.6)	1	1	1			
200–500	11/428 (2.6)	2.1 (0.4 – 11.6)	1.33 (0.4 – 4.3)	1.6 (0.6 – 4.2)			
<200	4/104 (3.9)	2.2 (0.2 – 24)	2.5 (0.6 – 11)	2.5 (0.7 – 8.6)			
<u>Additional Covariates</u>							
WAZ* at birth > -2	12/876 (1.4)	1	1	1	1.00		
WAZ at birth -2, >-3	6/71 (8.5)	2.9 (0.3–26)	7 (2 – 24.3)	6.7 (2.4 – 18.3)	5.2 (1.8–14.8)	0.002	
WAZ at birth -3	4/41 (9.8)	5.5 (0.6 – 49)	6.2 (1.4– 26.7)	7.8 (2.4 – 25.3)	6.2 (1.8–21.3)	0.004	
Illegal substances in pregnancy?							
No	21/901 (2.3)	1	1	1			
Yes	1/83 (1.2)	--	15 (0.9 – 258)	0.5 (0.07 – 3.9)			
Alcohol use this pregnancy?							
No(never)	15/630 (2.4)	1.00	1.00	1			
Yes	7/351 (2)	0.6 (0.1 – 3)	2.2 (0.7 – 6.8)	0.8 (0.3 – 2.1)			

* WAZ: Weight for Age Z score